Company: GEHC
Filing Date: 2025-04-30
Form Type: 10-Q
Source: 0001932393-25-000014
Chunk: 112

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-04-30
Form: 10-Q
Item: Item 2
Chunk 112
---
3120252024Sales of products$3,117$3,045Sales of services1,6601,605Total revenues4,7774,650Cost of products1,9631,967Cost of services802782Gross profit2,0121,902Selling, general, and administrative1,0401,038Research and development344324Total operating expenses1,3831,362Operating income629540Interest and other financial charges – net110122Non-operating benefit (income) costs(74)(102)Other (income) expense – net(99)8Income before income taxes692512Benefit (provision) for income taxes(104)(124)Net income588388Net (income) loss attributable to noncontrolling interests(24)(14)Net income attributable to GE HealthCare$564$374

TOTAL REVENUES.

Revenues by SegmentFor the three months ended March 3120252024 % change % organic* changeSegment revenuesImaging    $2,140$2,0624%5%AVS    1,2391,2271%3%PCS    7537471%2%PDx    6325996%8%Other(1)     1315Total revenues    $4,777$4,6503%4%

(1) Financial information not presented within the reportable segments, shown within the Other category, represents HealthCare Financial Services which does not meet the definition of an operating segment.

Revenues by RegionFor the three months ended March 3120252024 % changeUnited States and Canada (“USCAN”)    $2,237$2,0937%Europe, the Middle East, and Africa (“EMEA”)    1,1741,174—%China region    593597(1)%Rest of World    773785(2)%Total revenues    $4,777$4,6503%

For the three months ended March 31, 2025

Total revenues were $4,777 million, growing 3% as reported and 4% organically*. Sales of products increased 2% or $71 million with strong growth in USCAN, led by PDx and Imaging segment revenues. Sales of services increased 3% or $56 million primarily driven by growth in new and existing customer contractual agreements.

____________________

*Non-GAAP Financial Measure

29

Table of Contents                 

The segment revenues